Physician profile
Amanda C Caldwell
NPI 1871954552
$203,488.11
in general payments reported to CMS, 2019-2025
29 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,045 · 2022: $6,001 · 2023: $33K · 2024: $62K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Travel and Lodging: $29K · Food and Beverage: $15K · Consulting Fee: $6,920 · Education: $493 · Honoraria: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $143,142.50 |
| Travel and Lodging | $28,923.27 |
| Food and Beverage | $14,657.78 |
| Consulting Fee | $6,920.00 |
| Education | $493.44 |
| Honoraria | $305.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $113,355.09 | 2021-2025 | Tremfya, Simponi Aria |
| Galderma Laboratories, L.P. | $46,954.82 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Amgen INC. | $13,471.53 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $5,188.46 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $3,622.91 | 2021-2025 | |
| Almirall LLC | $3,310.24 | 2021-2025 | Seysara |
| Leo Pharma INC. | $3,200.05 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $2,754.37 | 2021-2025 | |
| Incyte Corporation | $1,628.02 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $1,537.50 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $1,205.66 | 2022-2023 | Tremfya |
| Dermavant Sciences, INC. | $1,202.46 | 2022-2024 | Vtama |
| Regeneron Pharmaceuticals, INC. | $1,107.00 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $900.13 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $838.40 | 2021-2025 | Winlevi, Ilumya, Blu-U |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $813.49 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $486.94 | 2021-2025 | |
| Lilly USA, LLC | $449.13 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $395.94 | 2021-2025 | |
| Allergan, INC. | $332.15 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $294.37 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.64 | 2021-2024 | Cabtreo |
| Collegium Pharmaceutical, INC. | $45.98 | 2024 | Xtampza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.36 | 2023 | Spevigo, Cyltezo |
| Organon LLC | $39.29 | 2025 | Vtama |
| Genentech USA, INC. | $28.73 | 2022-2025 | Xolair |
| Novo Nordisk INC | $23.52 | 2025 | Ozempic, Rybelsus |
| Journey Medical Corporation | $17.04 | 2025 | |
| Kyowa Kirin, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.